Arcus Biosciences, Inc. (RCUS) Current Ratio
- Current ratio · latest quarter: Value 3.82×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 3.82× | Current assets / current liabilities. $756.00M ÷ $198.00M ≈ 3.82× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 756.00M USD | Assets, Current |
| Current obligations | 198.00M USD | Liabilities, Current |
| Cash and equivalents | 150.00M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 552.00M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 34.00M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $756.00M | $198.00M | $150.00M | $552.00M | (m) | (m) | $34.00M | (m) | 3.82× |
| 2026-03-31 | $844.00M | $209.00M | $201.00M | $621.00M | (m) | (m) | $39.00M | (m) | 4.04× |
| 2025-12-31 | $1.01B | $231.00M | $222.00M | $759.00M | (m) | (m) | $42.00M | (m) | 4.36× |
| 2025-09-30 | $857.00M | $235.00M | $238.00M | $593.00M | (m) | (m) | $42.00M | (m) | 3.65× |
| 2025-06-30 | $946.00M | $210.00M | $248.00M | $663.00M | (m) | (m) | $29.00M | (m) | 4.50× |
| 2025-03-31 | $1.03B | $192.00M | $192.00M | $805.00M | (m) | (m) | $22.00M | (m) | 5.37× |
| 2024-12-31 | $1.02B | $226.00M | $150.00M | $828.00M | (m) | (m) | $18.00M | (m) | 4.50× |
| 2024-09-30 | $1.13B | $215.00M | $201.00M | $888.00M | (m) | (m) | $13.00M | (m) | 5.24× |
| 2024-06-30 | $1.02B | $199.00M | $156.00M | $813.00M | (m) | (m) | $15.00M | (m) | 5.14× |
| 2024-03-31 | $1.06B | $204.00M | $185.00M | $810.00M | (m) | (m) | $16.00M | (m) | 5.22× |
| 2023-12-31 | $831.00M | $184.00M | $127.00M | $632.00M | (m) | (m) | $17.00M | (m) | 4.52× |
| 2023-09-30 | $882.00M | $200.00M | $184.00M | $615.00M | (m) | (m) | $17.00M | (m) | 4.41× |
| 2023-06-30 | $986.00M | $180.00M | $230.00M | $700.00M | (m) | (m) | $12.00M | (m) | 5.48× |
| 2023-03-31 | $1.01B | $179.00M | $238.00M | $716.00M | (m) | (m) | $28.00M | (m) | 5.67× |
| 2022-12-31 | $1.07B | $193.00M | $206.00M | $803.00M | (m) | (m) | $20.00M | (m) | 5.53× |
| 2022-09-30 | $1.10B | $177.18M | $217.65M | $831.13M | (m) | (m) | $10.55M | (m) | 6.21× |
| 2022-06-30 | $1.23B | $164.02M | $272.63M | $900.15M | (m) | (m) | $21.98M | (m) | 7.48× |
| 2022-03-31 | $1.26B | $161.25M | $548.78M | $664.75M | (m) | (m) | $18.09M | (m) | 7.84× |
| 2021-12-31 | $1.26B | $166.00M | $148.00M | $351.00M | (m) | (m) | $10.00M | (m) | 7.60× |
| 2021-09-30 | $545.29M | $142.87M | $179.43M | $345.21M | (m) | (m) | $13.22M | (m) | 3.82× |
| 2021-06-30 | $745.95M | $130.37M | $320.48M | $400.53M | (m) | (m) | $16.96M | (m) | 5.72× |
| 2021-03-31 | $841.87M | $132.06M | $390.26M | $436.67M | (m) | (m) | $24.54M | (m) | 6.38× |
| 2020-12-31 | $735.82M | $121.67M | $173.41M | $555.23M | (m) | (m) | $15.68M | (m) | 6.05× |
| 2020-09-30 | $797.20M | $162.87M | $221.85M | $560.58M | (m) | (m) | $8.10M | (m) | 4.89× |
| 2020-06-30 | $471.60M | $40.02M | $285.19M | $177.29M | (m) | (m) | $12.05M | (m) | 11.78× |
| 2020-03-31 | $166.22M | $21.00M | $67.33M | $90.54M | (m) | (m) | $2.43M | (m) | 7.91× |
| 2019-12-31 | $192.71M | $22.71M | $57.94M | $130.33M | (m) | (m) | $4.70M | (m) | 8.49× |
| 2019-09-30 | $200.49M | $21.06M | $78.99M | $112.00M | (m) | (m) | $2.90M | (m) | 9.52× |
| 2019-06-30 | $227.73M | $26.51M | $76.07M | $148.33M | (m) | (m) | $2.45M | (m) | 8.59× |
| 2019-03-31 | $245.01M | $19.00M | $68.50M | $173.44M | (m) | (m) | $2.83M | (m) | 12.89× |
| 2018-12-31 | $258.95M | $16.93M | $71.06M | $185.48M | (m) | (m) | $3.10M | (m) | 15.29× |
| 2018-09-30 | $265.28M | $16.61M | $74.89M | $182.95M | (m) | (m) | $2.11M | (m) | 15.97× |
| 2018-06-30 | $267.44M | $16.38M | $170.00M | $95.70M | (m) | (m) | $5.39M | (m) | 16.33× |
| 2018-03-31 | $282.07M | $14.26M | $198.12M | $82.06M | (m) | (m) | $3.92M | (m) | 19.78× |
| 2017-12-31 | $176.87M | $12.73M | $98.43M | $77.28M | (m) | (m) | $3.82M | (m) | 13.90× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |